Clinical Trial: ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188025) titled 'ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer' on Sept. 03.

Brief Summary: The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery.

The main research question the REACT study aims to answer is:

- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery?

Interventions:

- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles C...